文献速递妇科

L1CAM表达联合ProMisE在子宫内膜癌中的预后意义

Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2023-05-24

本回顾性队列研究纳入162例子宫内膜癌患者,按ProMisE分子分型并检测L1CAM、β-catenin和PD-L1表达。L1CAM阳性是无进展生存期的独立不良预后因素(aHR 3.207),且在p53野生型亚组中进一步分层复发风险(aHR 4.906),而β-catenin和PD-L1无预后信息。

要点

  • L1CAM阳性是子宫内膜癌无进展生存期的独立不良预后因素(aHR 3.207)。
  • 在p53野生型亚组中,L1CAM阳性与更差的无进展生存期相关(aHR 4.906)。
  • β-catenin和PD-L1阳性与复发无关(P=0.462和P=0.152)。

核心结论

  • L1CAM阳性与子宫内膜癌不良预后相关,并在p53野生型亚组中进一步分层复发风险,而β-catenin和PD-L1对风险分层无信息价值。

研究设计与样本

  • 回顾性队列研究,纳入2014年1月至2018年12月单中心接受初次手术治疗的162例子宫内膜癌患者,按ProMisE分类。

主要发现

  • ProMisE分类将48例(29.6%)归为MMR缺陷型、16例(9.9%)为POLE突变型、72例(44.4%)为p53野生型、26例(16.0%)为p53异常型。
  • L1CAM阳性是无进展生存期的独立不良预后因素(aHR 3.207;95%CI 1.432-7.187;P=0.005)。
  • β-catenin和PD-L1阳性与复发无关(P=0.462和P=0.152)。
  • 在p53野生型亚组中,L1CAM阳性与更差的无进展生存期相关(aHR 4.906;95%CI 1.685-14.287;P=0.004)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the prognostic significance of L1 cell-adhesion molecule (L1CAM), β-catenin, and programmed death-ligand 1 (PD-L1) in endometrial cancer (EC) patients, with a focus on p53 wild-type subgroup, for additional risk stratification. METHODS: This retrospective cohort study included EC patients classified according to Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) who underwent primary surgical treatment at the single center between January 2014 and December 2018. Immunohistochemical staining was performed for four mismatch repair (MMR) proteins, p53, L1CAM, β-catenin, and PD-L1. DNA polymerase epsilon (POLE) mutation was detected by hot spot sequencing via droplet digital polymerase chain reaction. Survival outcome of each subgroup of L1CAM, β-catenin, and PD-L1 was measured according to their expression. RESULTS: A total of 162 EC patients were included. Endometrioid histologic type and early-stage disease were 140 (86.4%) and 109 (67.3%), respectively. ProMisE classification assigned 48 (29.6%), 16 (9.9%), 72 (44.4%), and 26 (16.0%) patients to MMR-deficient, POLE-mutated, p53 wild-type, and p53 abnormal subgroups, respectively. L1CAM was identified as an independent poor prognostic factor for progression-free survival (PFS; adjusted hazard ratio [aHR], 3.207; 95% confidence interval (CI), 1.432-7.187; P = 0.005), whereas β-catenin and PD-L1 positivity were not associated with recurrence (P = 0.462 and P = 0.152, respectively). In p53 wild-type subgroup, L1CAM positivity was associated with worse PFS (aHR, 4.906; 95% CI, 1.685-14.287; P = 0.004). CONCLUSION: L1CAM positivity was associated with poor prognosis in EC and further stratified the risk of recurrence in p53 wild-type subgroup, whereas β-catenin and PD-L1 were not informative for risk stratification.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kim J, Kim SI, Kim NR, et al. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer. Gynecol Oncol. 2023. PMID: 37236032. doi:10.1016/j.ygyno.2023.05.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。